No benefit from flexible titration above minimum licensed dose in prescribing antidepressants for major depression: systematic review-Reference-Cited by-同舟云学术

No benefit from flexible titration above minimum licensed dose in prescribing antidepressants for major depression: systematic review

Published:2020-01-17 Issue:5 Volume:141 Page:401-409
ISSN:0001-690X
Container-title:Acta Psychiatrica Scandinavica
language:en
Short-container-title:Acta Psychiatr Scand

Author:

Furukawa T. A.¹^ORCID,Salanti G.²,Cowen P. J.³,Leucht S.⁴,Cipriani A.³⁵

Affiliation:

1. Departments of Health Promotion and Human Behavior and of Clinical Epidemiology Kyoto University Graduate School of Medicine/School of Public Health Kyoto Japan

2. Institute of Social and Preventive Medicine (ISPM) University of Bern Bern Switzerland

3. Department of Psychiatry Warneford Hospital University of Oxford Oxford UK

4. Department of Psychiatry and Psychotherapy School of Medicine Technical University of Munich Munich Germany

5. Oxford Health NHS Foundation Trust Warneford Hospital Oxford UK

Funder

Japan Society for the Promotion of Science London

National Institute for Social Care and Health Research

Publisher

Wiley

Subject

Psychiatry and Mental health

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/acps.13145

Reference28 articles.

1. Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis

2. Which antidepressant doses are optimal?

3. Optimal dosing of antidepressant drugs

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Scientific Autobiography of a Japanese Psychiatrist Turned Cognitive-Behavioral Therapist, Clinical Epidemiologist and Smartphone App Developer;The American Journal of Geriatric Psychiatry;2024-09

2. Management of Depression in Adults;JAMA;2024-07-09

3. Participant and trial characteristics reported in predictive analyses of trial attrition: An umbrella review of systematic reviews of randomised controlled trials across multiple conditions;2024-06-07

4. Treatment Outcomes With Licensed and Unlicensed Stimulant Doses for Adults With Attention-Deficit/Hyperactivity Disorder;JAMA Psychiatry;2023-10-25

5. Complexities of treatment‐resistant depression: cautionary notes and promising avenues;World Psychiatry;2023-09-15